oxazolidin-2-one has been researched along with evacetrapib in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (95.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Einecke, D | 1 |
| Fisher, EA; Hewing, B | 1 |
| Duivenvoorden, R; Fayad, ZA | 1 |
| Goldberg, AS; Hegele, RA | 1 |
| Bochem, AE; Kuivenhoven, JA; Stroes, ES | 1 |
| Ballantyne, CM; Catapano, AL; Norata, GD | 1 |
| Akhlaghi, F; Mohammadpour, AH | 1 |
| Escribano, A; Mantlo, NB | 1 |
| Cai, J; Chen, C; Hu, Z; Li, C; Li, Y; Liu, L; Luo, H; Pei, F; Zeng, C; Zhang, W; Zhou, F; Zhou, L | 1 |
| deGoma, EM; Rader, DJ | 1 |
| Berthold, HK; Gouni-Berthold, I | 1 |
| McCullough, PA; Shin, HJ | 1 |
| Inazu, A; Mabuchi, H; Nohara, A | 1 |
| Friedrich, S; Hall, SD; Ke, AB; Mantlo, N; Rotelli, M; Small, DS | 1 |
| Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA | 1 |
| Boekholdt, SM; Hovingh, GK; Ray, KK | 1 |
| Quintão, EC | 1 |
| Barkas, F; Elisaf, M; Filippatos, TD; Klouras, E | 1 |
| Crucet, M; Doycheva, P; Giral, H; Jukema, JW; Kratzer, A; Kühnast, S; Landmesser, U; Lüscher, TF; Mocharla, P; Osto, E; Princen, HM; Simic, B; Speer, T; Staels, B; Stivala, S; Tailleux, A; van der Hoorn, JW | 1 |
| Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS | 1 |
| Ding, Q; Fan, J; Liu, Z; Niimi, M; Wang, L; Wang, Z; Xu, J; Zhang, J | 1 |
| Cao, Y; Hao, D; Yang, Z; Yuan, X; Zhang, L; Zhang, S | 1 |
| Corsini, A; Macchi, C; Matsuzawa, Y; Ruscica, M; Sirtori, CR; Yamashita, S | 1 |
| Bis, JC; Charoen, P; Chaturvedi, N; Drenos, F; Finan, C; Franceschini, N; Gaunt, TR; Giambartolomei, C; Gordillo-Marañón, M; Hingorani, AD; Hughes, AD; Hunt, NB; Kivimaki, M; Lawlor, DA; Mook-Kanamori, DO; O'Donnell, CJ; Papacosta, O; Price, JF; Schmidt, AF; Sofat, R; Wannamethee, G; Wong, A; Zwierzyna, M | 1 |
16 review(s) available for oxazolidin-2-one and evacetrapib
| Article | Year |
|---|---|
Rationale for cholesteryl ester transfer protein inhibition.
Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Drug Discovery; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2012 |
Safety of CETP inhibition.
Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Oxazolidinones; Quinolines; Safety; Sulfhydryl Compounds | 2012 |
Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Dyslipidemias; Esters; Humans; Lipoproteins, HDL; Oxazolidinones; Sulfhydryl Compounds | 2012 |
The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease.
Topics: Animals; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Oxazolidinones | 2013 |
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2013 |
Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
Topics: Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Drug Discovery; Humans; Oxazolidinones; Risk Factors; Structure-Activity Relationship | 2014 |
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
Topics: Adult; Amides; Anticholesteremic Agents; Benzodiazepines; Blood Pressure; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome; Triglycerides | 2013 |
Future of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2014 |
Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Benzimidazoles; Benzodiazepines; Humans; Hyperlipoproteinemia Type II; Oligonucleotides; Oxazolidinones | 2014 |
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Esters; Heart Diseases; Humans; Hyperlipoproteinemias; Kidney Diseases; Liver; Niacin; Observational Studies as Topic; Oxazolidinones; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Risk; Sulfhydryl Compounds; Triglycerides; White People | 2014 |
Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Topics: Animals; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Humans; Lipid Metabolism, Inborn Errors; Oxazolidinones | 2014 |
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds | 2016 |
Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Lipids; Lipoprotein(a); Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2016 |
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome | 2017 |
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Lignans; Lipoproteins, HDL; Lipoproteins, VLDL; Oxazolidinones; Probucol; Quinolines; Sulfhydryl Compounds; Triglycerides | 2018 |
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Humans; Mendelian Randomization Analysis; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2021 |
8 other study(ies) available for oxazolidin-2-one and evacetrapib
| Article | Year |
|---|---|
[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Topics: Acute Coronary Syndrome; Amides; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Drugs, Investigational; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Oxazolidinones; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2011 |
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2013 |
Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.
Topics: Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Half-Life; Humans; Models, Biological; Oxazolidinones; Time Factors | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Aryldialkylphosphatase; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Humans; Mice, Transgenic; Oxazolidinones; Phenotype; Reactive Oxygen Species; Triglycerides; Up-Regulation; Vasodilation | 2017 |
Comparative studies of three cholesteryl ester transfer proteins and their interactions with known inhibitors.
Topics: Animals; Anticholesteremic Agents; Benzodiazepines; Binding Sites; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Guinea Pigs; Lipoproteins, LDL; Male; Molecular Dynamics Simulation; Oxazolidinones; Phylogeny; Protein Structure, Tertiary; Rabbits; Triglycerides | 2017 |
Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
Topics: Anticholesteremic Agents; Benzodiazepines; Binding Sites; Cholesterol Ester Transfer Proteins; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxazolidinones; Protein Binding; Protein Structure, Secondary; Quinolines; Solvents; Thermodynamics | 2018 |